CNS
Regeneron announces results for preventing lean mass and muscle loss during GLP-1 weight loss
Results show trevogrumab prevents lean mass and muscle loss during GLP-1 weight loss
Regeneron’s New Drug Application for cemdisiran accepted for review by FDA and EMA
Globally, around 150 to 200 out of every million people have myasthenia gravis
Regeneron agrees research collaboration with Parabilis Medicines
Regeneron will pay Parabilis $125m upfront, with up to $2.2bn in potential milestone payments and royalties
Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD
Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed
Regeneron’s Libtayo receives EC approval for skin cancer
Phase 3 trial results showed the drug significantly improved disease-free survival
The power of representation, innovation and trust in rare disease clinical trials
By Carol Pitcher-Towner
Sanofi/Regeneron’s Dupixent granted FDA approval for bullous pemphigoid
Around 27,000 adults in the US are living with uncontrolled cases of the chronic skin disease
Sanofi/Regeneron share results for Dupixent in atopic dermatitis patients with darker skin tones
These are the first clinical study results for the drug in a large population of patients with darker skin tones
Alnylam’s RNAi therapeutic vutrisiran recommended by CHMP for rare heart disease
The committee has recommended the drug for both wild type and hereditary ATTR-CM
Regeneron’s bispecific antibody Lynozyfic approved by EC to treat multiple myeloma
More than 35,000 new cases of the blood cancer are diagnosed in Europe every year
Sanofi/Regeneron’s Dupixent granted FDA approval for chronic spontaneous urticaria
More than 300,000 people in the US are living with uncontrolled cases of the inflammatory skin disease
Sanofi and Regeneron’s Dupixent granted FDA priority review for bullous pemphigoid
Approximately 27,000 adults in the US are living with uncontrolled cases of the skin disease